首页> 外国专利> Pyrimido5,4-b1,4oxazine derivatives, process for their preparation, medicament containing them and intermediate pyrimido5,4-b1,4oxazine derivatives.

Pyrimido5,4-b1,4oxazine derivatives, process for their preparation, medicament containing them and intermediate pyrimido5,4-b1,4oxazine derivatives.

机译:嘧啶并[5,4-b] [1,4]恶嗪衍生物,其制备方法,含有它们的药物和中间体嘧啶并[5,4-b] [1,4]恶嗪衍生物。

摘要

The invention relates to novel pyrimido [5,4-b][1,4]oxazine derivatives of the formula (I), and the acid addition salts thereof, pharmaceutical compositions containing them and a process for their preparation. In the formula (I) IMAGE (I) wherein R1 stands for a C1-4 alkyl group R2 stands for hydrogen or halogen or an azido group or an -NR5R6 group, wherein R5 represents hydrogen or a benzyl group, or a C1-4 alkyl group unsubstituted or substituted by a hydroxyl group, R6 stands for hydrogen, an amino group, a C3-6 cycloalkyl group, a straight or branched-chain C1-4 alkyl group optionally substituted by a hydroxyl, mercapto, aminocarbonyl, furyl, 2-benzo[1,4]dioxanyl, di(C1-4 alkyl)amino group or by a phenyl or phenoxy group optionally mono- or polysubstituted by halogen or C1-4 alkoxy group (s) or by a 6-membered, saturated nitrogen-containing heterocycle optionally containing an additional nitrogen or oxygen atom and optionally substituted by a C1-4 alkyl or benzyl group further NR5R6 may also represents a 6-membered, saturated, nitrogen-containing heterocycle optionally containing an additional nitrogen or oxygen atom and optionally substituted by a C2-4 alkoxycarbonyl or C1-4 hydroxyalkyl group R3 and R4 are the same or different and stand for hydrogen or a C1-4 alkyl group R9 stands for hydrogen or a C1-4 alkyl group unsubstituted or monosubstituted by an oxo, cyano, aminocarbonyl, C2-5 alkoxycarbonyl, pyridiyl, morpholinocarbonyl, or phenyl group or mono- or polysubstituted by OH group(s), with the proviso that R2 is different from chlorine, 4-morpholinyl and piperidyl group when R9 stands for hydrogen or R2 is different from chlorine and 4-morpholinyl group when R9 stands for a methyl or benzyl group. The compounds of the formula (I) are capable to increase the myocardial contractile force (the performance of the failing heart) and the coronary blood flow, thus they can therapeutically be used for the treatment of the chronic heart failure and coronary disturbances.
机译:本发明涉及式(I)的新型嘧啶并[5,4-b] [1,4]恶嗪衍生物及其酸加成盐,包含它们的药物组合物及其制备方法。在式(I)中,其中R 1代表C 1-4烷基,R 2代表氢或卤素或叠氮基或-NR 5 R 6,其中R 5代表氢或苄基,或C 1。 -4未取代或被羟基取代的烷基,R6代表氢,氨基,C3-6环烷基,直链或支链C1-4烷基,可任选被羟基,巯基,氨基羰基,呋喃基取代,2-苯并[1,4]二恶烷基,二(C1-4烷基)氨基或被苯基或苯氧基取代,所述苯基或苯氧基任选被卤素或C1-4烷氧基或6-元单或多取代,任选地包含另外的氮或氧原子并且任选地被C 1-4烷基或苄基取代的饱和的含氮杂环进一步的NR 5 R 6也可以表示任选地包含另外的氮或氧原子的6元饱和的含氮杂环,并且任选地被C2-4烷氧羰基或C1-4羟基取代烷基R 3和R 4相同或不同,代表氢或C 1-4烷基,R 9代表氢或未被氧代,氰基,氨基羰基,C 2-5烷氧羰基,吡啶基取代或未取代的氢或C 1-4烷基,吗啉代羰基或苯基,或被OH基单取代或多取代,前提是R9代表氢时R2与氯,4-吗啉基和哌啶基不同,或者当R9与氢,4-吗啉基和哌啶基不同时R 9代表甲基或苄基。式(I)的化合物能够增加心肌收缩力(心脏衰竭的表现)和冠状动脉血流量,因此它们可以治疗性地用于治疗慢性心力衰竭和冠状动脉疾病。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号